"Mostly it's been a discussion of the patients needing cheaper drugs and the large pharmaceutical companies wanting to maintain their prices in the U.S., " says Byron Cryer, a gastroenterologist at the UniversityofTexasSouthwesternMedicalSchool and one of the authors of the Fosamax paper.